论文部分内容阅读
目的:观察紫杉醇/奥沙利铂/5-氟尿嘧啶方案治疗晚期或转移性胃癌的客观疗效、疾病进展时间、生存时间和毒性反应。方法:入选31例晚期或转移性胃癌患者接受紫杉醇80~100mg·m-2(d1,d8),奥沙利铂130mg·m-2(d2),5-氟尿嘧啶400~500mg·m-2(d2~6),21d为1周期,疗程2~6周期。结果:总有效率为51.6%,中位疾病进展时间(TTP)为5个多月,中位生存时间(MST)为13个月,1年生存率为41.9%,2年生存率为13%。常见的毒性反应为白细胞和中性粒细胞减低、腹泻和周围神经毒性反应等。结论:紫杉醇/奥沙利铂/5-氟尿嘧啶联合化疗方案治疗晚期或转移性胃癌的疗效显著、耐受性较好。
Objective: To observe the objective efficacy, duration of disease progression, survival time and toxicity of paclitaxel / oxaliplatin / 5-fluorouracil regimen in the treatment of advanced or metastatic gastric cancer. Methods: Totally 31 patients with advanced or metastatic gastric cancer received paclitaxel 80 ~ 100 mg · m-2 (d1, d8), oxaliplatin 130 mg · m-2 (d2) and 5- fluorouracil 400 ~ 500 mg · m- d2 ~ 6), 21d for a period of 2 to 6 cycles of treatment. Results: The total effective rate was 51.6%, the median time to progression (TTP) was more than 5 months, the median survival time (MST) was 13 months, the 1-year survival rate was 41.9%, and the 2-year survival rate was 13% . Common toxic reactions are leukopenia and neutropenia, diarrhea and peripheral neurotoxic reactions. Conclusions: The combination of paclitaxel / oxaliplatin and 5-fluorouracil combined with chemotherapy has significant effect and good tolerability in the treatment of advanced or metastatic gastric cancer.